Evidence map›Paper›PMID 36639190›Full record

ArticleBMJ health & care informatics2023

Finding undiagnosed patients with hepatitis C virus: an application of machine learning to US ambulatory electronic medical records.

John Rigg, Orla Doyle, Niamh McDonogh, Nadea Leavitt, Rehan Ali, Annie Son, Bruce Kreter

Open access · goldAbstract read
In one paragraph

Article in BMJ health & care informatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. [Diagnosis and treatment of liver diseases in the era of artificial intelligence].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

John RiggAI for Healthcare & MedTech, IQVIA Inc, London, UK.
Orla DoyleAI for Healthcare & MedTech, IQVIA Inc, London, UK.
Niamh McDonoghAI for Healthcare & MedTech, IQVIA Inc, London, UK.
Nadea LeavittAI for Healthcare & MedTech, IQVIA, Plymouth Meeting, Pennsylvania, USA.
Rehan AliAI for Healthcare & MedTech, IQVIA Inc, London, UK rehan.ali@iqvia.com.ORCID http://orcid.org/0000-0003-3182-2106
Annie SonMedical Affairs, Gilead Sciences Inc, Foster City, California, USA.
Bruce KreterMedical Affairs, Gilead Sciences Inc, Foster City, California, USA.
IQVIA (United Kingdom) · GBGilead Sciences (United States) · USIQVIA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo develop and validate a machine learning (ML) algorithm to identify undiagnosed hepatitis C virus (HCV) patients, in order to facilitate prioritisation of patients for targeted HCV screening.

methodsThis retrospective study used ambulatory electronic medical records (EMR) from January 2015 to February 2020. A Gradient Boosting Trees algorithm was trained using patient records to predict initial HCV diagnosis and was validated on a temporally independent held-out cross-section of the data. The fold improvement in precision (proportion of patients identified by the algorithm who are HCV positive) over universal screening was examined and compared with risk-based screening.

results21 508 positive (HCV diagnosed) and 28.2M unlabelled (lacking evidence of HCV diagnosis) patients met the inclusion criteria for the study. After down-sampling unlabelled patients to aid the algorithm's learning process, 16.2M unlabelled patients entered the analysis. Performance of the algorithm was compared with universal screening on the held-out cross-section, which had an incidence of HCV diagnoses of 0.02%. The algorithm achieved a 101.0 ×, 18.0 × and 5.1 × fold improvement in precision over universal screening at 5%, 20% and 50% levels of recall. When compared with risk-based screening, the algorithm required fewer patients to be screened and improved precision.

conclusionsThis study presents strong evidence towards the use of ML on EMR data for the prioritisation of patients for targeted HCV testing with potential to improve efficiency of resource utilisation, thereby reducing the workload for clinicians and saving healthcare costs. A prospective interventional study would allow for further validation before use in a clinical setting.

Indexed as

HepacivirusHepatitis CElectronic Health RecordsHumansMachine LearningProspective StudiesRetrospective StudiesData ScienceDecision TreesElectronic Health RecordsMachine LearningPublic health informatics

Identifiers

PMID36639190
PMCPMC9843171
OpenAlexW4316174663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.